SCHEMBL3540984

SCHEMBL3540984

Cn1c(-c2n[nH]c3c(F)cccc23)nc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.44
GSK3B P49841 1/20 0.44
KDM4E B2RXH2 8/20 0.43
GAA P10253 5/20 0.43
LMNA P02545 3/20 0.43
PAX8 Q06710 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 8/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
TP53 P04637 5/20 0.42
PKM P14618 4/20 0.42
HSD17B10 Q99714 3/20 0.42
ALOX15 P16050 1/20 0.42
PDGFRB P09619 1/20 0.41
FGFR1 P11362 1/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534930 0.85 SMN1; SMN2 (0.45) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL3541251 0.82 RAB9A (0.45) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL3535157 0.80 ALDH1A1 (0.50) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL3541944 0.80 KDM4E (0.46) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL3535167 0.77 RAB9A (0.45) KDM4EKMT2AALDH1A1NPC1RAB9A
SCHEMBL3542577 0.77 KHK (0.41) KDM4EGAAALDH1A1RAB9APDGFRB
SCHEMBL3540321 0.76 MAP2K4 (0.55) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL30145320 0.74 MEN1 (0.54) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL22344209 0.74 MEN1 (0.54) RPS6KB1GSK3BKDM4EGAALMNA
SCHEMBL3534827 0.73 LRRK2 (0.42) RPS6KB1GSK3BKDM4EGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK RPS6KB1 1678/4885GSK3B 409/4885KDM4E 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.